Adverse effects: specific ‐ doctors' assessment of adverse effects UKU (events) Medium‐term · people in the prodromal stage of psychosis
It is very uncertain whether group C cognitive behavioural therapy: cognitive behavioural therapy… changes adverse effects: specific ‐ doctors' assessment of adverse effects… compared with supportive therapy + placebo (very low certainty).
1 finding from 1 review
Adverse effects: 1. Sedation · patients with schizophrenia
It is very uncertain whether ZUCLOPENTHIXOL DIHYDROCHLORIDE changes adverse effects: Sedation compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Other adverse effects, general and specific · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse effects, general and specific · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects. Specific: movement disorders ‐ parkinsonism · patients with schizophrenia
HALOPERIDOL probably leads to higher adverse effects: Movement disorders ‐ parkinsonism compared with PLACEBO (moderate certainty).
1 finding from 1 review
Severe adverse effects ‐ medium term ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: Incidence of serious adverse effects · adults with schizophrenia
It is very uncertain whether ASENAPINE changes adverse effects: Incidence of serious adverse effects compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects: Death ‐ long termOccurrences of death · patients with schizophrenia
ORAL FLUPHENAZINE showed no clear difference in adverse effects: Death ‐ long termOccurrences of death compared with PLACEBO (low certainty).
1 finding from 1 review
Adverse effects/events: incidence of adverse effects/events · patients with schizophrenia
1 finding from 1 review
Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) · adults with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Weight gain · patients with schizophrenia
BIFEPRUNOX showed no clear difference in adverse effects: Weight ‐ Total number of participants with ≥ 7%… compared with PLACEBO (moderate certainty).
1 finding from 1 review
Adverse effects: extrapyramidal adverse effectsParkinsonism (rigidity) short term (< 3 months) Clinical diagnoses · patients with schizophrenia
ORAL FLUPHENAZINE probably leads to higher adverse effects: Extrapyramidal effects (rigidity) ‐ short… compared with PLACEBO (moderate certainty).
1 finding from 1 review
Adverse effects: 2. Extrapyramidal ‐ akathisia · patients with schizophrenia
ORAL FLUPHENAZINE probably leads to higher adverse effects: Extrapyramidal effects (akathisia) ‐ short… compared with PLACEBO (moderate certainty).
1 finding from 1 review
Severe adverse effects ‐ short term Numbers of participants leaving the studies due to severe adverse effects · patients with schizophrenia
It is very uncertain whether TRIFLUOPERAZINE changes severe adverse effects ‐ short term Numbers of participants leaving… compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects: 1a. extrapyramidal ‐ various effects ‐ short term (up to 12 weeks) ‐ general ‐ any significant EPS · patients with schizophrenia
RISPERIDONE may leads to higher adverse effects: 1a. extrapyramidal ‐ various effects ‐ short term… compared with PLACEBO (low certainty).
1 finding from 1 review
Adverse effects ‐ stiffness · patients with schizophrenia
Bromperidol decanoate showed no clear difference in adverse effects ‐ stiffness compared with placebo (low certainty).
1 finding from 1 review
Adverse effects ‐ not reported · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects ‐ not reported · male 45.2 (mean) years old patients with schizophrenia and antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found